Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Bernard Pillegand

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects With Normal or Impaired Hepatic Function

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2000

English

Related publications

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1999

English

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function

Clinical Pharmacology in Drug Development

Pharmacology

Pharmaceutical Science

2019

English

Synaptic Dysfunction in Human Immunodeficiency Virus Type-1-Positive Subjects: Inflammation or Impaired Neuronal Plasticity?

Journal of Internal Medicine

Internal Medicine

2013

English

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects With Normal or Varying Degrees of Impaired Renal Function

Drugs in R and D

Pharmacology

2014

English

Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance

English

Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease Following Different Protease Inhibitor Treatments

English

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2000

English

Single-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in Patients With Human Immunodeficiency Virus Infection.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1997

English

Crystal Structure of Human Immunodeficiency Virus (HIV) Type 2 Protease in Complex With a Reduced Amide Inhibitor and Comparison With HIV-1 Protease Structures.

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

1993

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Bernard Pillegand

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects With Normal or Impaired Hepatic Function

Related publications

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function

Synaptic Dysfunction in Human Immunodeficiency Virus Type-1-Positive Subjects: Inflammation or Impaired Neuronal Plasticity?

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects With Normal or Varying Degrees of Impaired Renal Function

Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance

Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease Following Different Protease Inhibitor Treatments

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Single-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in Patients With Human Immunodeficiency Virus Infection.

Crystal Structure of Human Immunodeficiency Virus (HIV) Type 2 Protease in Complex With a Reduced Amide Inhibitor and Comparison With HIV-1 Protease Structures.